- Home
- ABSI vs RCKT Comparison
ABSI vs RCKT Comparison
Compare ABSI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | RCKT |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 997.8M | 401.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABSI | RCKT |
|---|---|---|
| Price | $7.49 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $6.96 | ★ $29.73 |
| AVG Volume (30 Days) | ★ 5.4M | 2.9M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,534,000.00 | N/A |
| Revenue This Year | $215.96 | N/A |
| Revenue Next Year | $319.10 | $64.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $2.40 |
| 52 Week High | $8.57 | $5.45 |
Technical Indicators
Market Signals| Indicator | ABSI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 65.45 |
| Support Level | $2.76 | $3.32 |
| Resistance Level | N/A | $4.04 |
| Average True Range (ATR) | 0.79 | 0.19 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 62.17 | 90.45 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.